Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease (2019)
Type of ContentConference Contributions - Published
PublisherFrontiers Media SA
- Science: Journal Articles 
The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET imaging to test for any association between cerebral amyloid deposition and cognitive impairment in PD, in a sample enriched for cases with mild cognitive impairment. This cross-sectional study used Movement Disorders Society level II criteria to classify 115 participants with PD as having normal cognition (PDN, n = 23), mild cognitive impairment (PD-MCI, n = 76), or dementia (PDD, n = 16). We acquired 18F-Florbetaben (FBB) amyloid PET and structural MRI. Amyloid deposition was assessed between the three cognitive groups, and also across the whole sample using continuous measures of both global cognitive status and average performance in memory domain tests. Outcomes were cortical FBB uptake, expressed in centiloids and as standardized uptake value ratios (SUVR) using the Centiloid Project whole cerebellum region as a reference, and regional SUVR measurements. FBB binding was higher in PDD, but this difference did not survive adjustment for the older age of the PDD group. We established a suitable centiloid cut-off for amyloid positivity in Parkinson's disease (31.3), but there was no association of FBB binding with global cognitive or memory scores. The failure to find an association between PET amyloid deposition and cognitive impairment in a moderately large sample, particularly given that it was enriched with PD-MCI patients at risk of dementia, suggests that amyloid pathology is not the primary driver of cognitive impairment and dementia in most patients with PD.
CitationMelzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Grenfell S, Horne K-L, Young BN, Pascoe MJ, Almuqbel MM, Wang J, Marsh SH, Miller DH, Dalrymple-Alford JC, Anderson TJ (2019). Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. FRONTIERS IN NEUROLOGY. 10. 391-.
This citation is automatically generated and may be unreliable. Use as a guide only.
KeywordsParkinson's disease; amyloid PET; Florbetaben; dementia; centiloid; mild cognitive impairment
ANZSRC Fields of Research11 - Medical and Health Sciences::1109 - Neurosciences::110904 - Neurology and Neuromuscular Diseases
11 - Medical and Health Sciences::1103 - Clinical Sciences::110320 - Radiology and Organ Imaging
51 - Physical sciences::5105 - Medical and biological physics::510502 - Medical physics
RightsCopyright © 2019 Melzer, Stark, Keenan, Myall, MacAskill, Pitcher, Livingston, Grenfell, Horne, Young, Pascoe, Almuqbel, Wang, Marsh, Miller, Dalrymple- Alford and Anderson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Showing items related by title, author, creator and subject.
Melzer TR; Stark MR; Keenan RJ; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Grenfell S; Horne KL; Young BN; Pascoe MJ; Almuqbel MM; Wang J; Miller DH; Anderson TJ; Marsh, Steven; Dalrymple-Alford, John (Frontiers Media SA, 2019)The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET ...
Almuqbel, M.; Melzer, T.R.; Myall, D.J.; MacAskill, M.R.; Livingston, L.; Wood, K-L.; Pitcher, T.L.; Keenan, R.J.; Dalrymple-Alford, J.C.; Anderson, T.J. (University of Canterbury. Psychology, 2015)
Wood KL; Myall DJ; Livingston L; Melzer TR; Pitcher TL; MacAskill MR; Geurtsen GJ; Anderson TJ; Dalrymple-Alford JC (2016)The Movement Disorder Society Task Force (MDS-TF) has proposed diagnostic criteria for mild cognitive impairment in Parkinson's disease (PD-MCI). We hypothesized that the risk of dementia (PDD) varies across the different ...